A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

NCT01721746 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

405

Enrollment

INDUSTRY

Sponsor class

Conditions

Unresectable or Metastatic Melanoma

Interventions

BIOLOGICAL: BMS-936558
DRUG: Dacarbazine
DRUG: Carboplatin
DRUG: Paclitaxel

Sponsor

Bristol-Myers Squibb